Rapidly progressive crescentic glomerulonephritis: Early treatment is a must

Gabriella Moroni, Claudio Ponticelli

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The term crescentic glomerulonephritis (GN) refers to a pathologic condition characterized by extracapillary proliferation in >. 50% of glomeruli. Clinically crescentic GN is characterized by a nephritic syndrome rapidly progressing to end stage renal disease (ESRD). Three types of crescentic GN have been identified. Type 1 includes cases of Goodpasture syndrome characterized by linear deposits of antibodies along the glomerular basement membrane (GBM) at immunofluorescence. Type 2 is a heterogeneous group of primary or secondary glomerular diseases complicated by crescentic GN. In this category there are granular deposits of immunoglobulins and complement fractions on the glomerular tuft. Type 3 includes cases of ANCA-associated small-vessel vasculitis. Immunofluorescence is negative or may show only faint deposits of immunoglobulins. The etiology and the initial pathogenetic factors are different in the three types, but the final mechanisms leading to crescent formation and the renal symptoms and signs are similar. The prognosis depends on the timeline of diagnosis and treatment. Although some patients requiring dialysis may recover a good renal function, usually the higher the serum creatinine at presentation the worse the outcome. When treatment is initiated early, most patients obtain a complete or partial remission. High-dose corticosteroids and cyclophosphamide represent the standard therapy for crescentic GN. The addition of plasma exchange may also be helpful, particularly in patients with massive alveolar hemorrhage. Anti-B monoclonal antibodies have also been used in some patients with crescentic GN, but their role in this particular area is still poorly established.

Original languageEnglish
Pages (from-to)723-729
Number of pages7
JournalAutoimmunity Reviews
Volume13
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Glomerulonephritis
Kidney
Fluorescent Antibody Technique
Immunoglobulins
Therapeutics
Anti-Glomerular Basement Membrane Disease
Antineutrophil Cytoplasmic Antibodies
Glomerular Basement Membrane
Plasma Exchange
Vasculitis
Cyclophosphamide
Signs and Symptoms
Chronic Kidney Failure
Dialysis
Creatinine
Adrenal Cortex Hormones
Monoclonal Antibodies
Hemorrhage
Antibodies
Serum

Keywords

  • ANCA-associated vasculitis (AAV)
  • End stage renal disease
  • Goodpasture syndrome
  • Rapidly progressive glomerulonephritis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Rapidly progressive crescentic glomerulonephritis : Early treatment is a must. / Moroni, Gabriella; Ponticelli, Claudio.

In: Autoimmunity Reviews, Vol. 13, No. 7, 2014, p. 723-729.

Research output: Contribution to journalArticle

@article{ea59e8f509894681a760a27794c8ea48,
title = "Rapidly progressive crescentic glomerulonephritis: Early treatment is a must",
abstract = "The term crescentic glomerulonephritis (GN) refers to a pathologic condition characterized by extracapillary proliferation in >. 50{\%} of glomeruli. Clinically crescentic GN is characterized by a nephritic syndrome rapidly progressing to end stage renal disease (ESRD). Three types of crescentic GN have been identified. Type 1 includes cases of Goodpasture syndrome characterized by linear deposits of antibodies along the glomerular basement membrane (GBM) at immunofluorescence. Type 2 is a heterogeneous group of primary or secondary glomerular diseases complicated by crescentic GN. In this category there are granular deposits of immunoglobulins and complement fractions on the glomerular tuft. Type 3 includes cases of ANCA-associated small-vessel vasculitis. Immunofluorescence is negative or may show only faint deposits of immunoglobulins. The etiology and the initial pathogenetic factors are different in the three types, but the final mechanisms leading to crescent formation and the renal symptoms and signs are similar. The prognosis depends on the timeline of diagnosis and treatment. Although some patients requiring dialysis may recover a good renal function, usually the higher the serum creatinine at presentation the worse the outcome. When treatment is initiated early, most patients obtain a complete or partial remission. High-dose corticosteroids and cyclophosphamide represent the standard therapy for crescentic GN. The addition of plasma exchange may also be helpful, particularly in patients with massive alveolar hemorrhage. Anti-B monoclonal antibodies have also been used in some patients with crescentic GN, but their role in this particular area is still poorly established.",
keywords = "ANCA-associated vasculitis (AAV), End stage renal disease, Goodpasture syndrome, Rapidly progressive glomerulonephritis",
author = "Gabriella Moroni and Claudio Ponticelli",
year = "2014",
doi = "10.1016/j.autrev.2014.02.007",
language = "English",
volume = "13",
pages = "723--729",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Rapidly progressive crescentic glomerulonephritis

T2 - Early treatment is a must

AU - Moroni, Gabriella

AU - Ponticelli, Claudio

PY - 2014

Y1 - 2014

N2 - The term crescentic glomerulonephritis (GN) refers to a pathologic condition characterized by extracapillary proliferation in >. 50% of glomeruli. Clinically crescentic GN is characterized by a nephritic syndrome rapidly progressing to end stage renal disease (ESRD). Three types of crescentic GN have been identified. Type 1 includes cases of Goodpasture syndrome characterized by linear deposits of antibodies along the glomerular basement membrane (GBM) at immunofluorescence. Type 2 is a heterogeneous group of primary or secondary glomerular diseases complicated by crescentic GN. In this category there are granular deposits of immunoglobulins and complement fractions on the glomerular tuft. Type 3 includes cases of ANCA-associated small-vessel vasculitis. Immunofluorescence is negative or may show only faint deposits of immunoglobulins. The etiology and the initial pathogenetic factors are different in the three types, but the final mechanisms leading to crescent formation and the renal symptoms and signs are similar. The prognosis depends on the timeline of diagnosis and treatment. Although some patients requiring dialysis may recover a good renal function, usually the higher the serum creatinine at presentation the worse the outcome. When treatment is initiated early, most patients obtain a complete or partial remission. High-dose corticosteroids and cyclophosphamide represent the standard therapy for crescentic GN. The addition of plasma exchange may also be helpful, particularly in patients with massive alveolar hemorrhage. Anti-B monoclonal antibodies have also been used in some patients with crescentic GN, but their role in this particular area is still poorly established.

AB - The term crescentic glomerulonephritis (GN) refers to a pathologic condition characterized by extracapillary proliferation in >. 50% of glomeruli. Clinically crescentic GN is characterized by a nephritic syndrome rapidly progressing to end stage renal disease (ESRD). Three types of crescentic GN have been identified. Type 1 includes cases of Goodpasture syndrome characterized by linear deposits of antibodies along the glomerular basement membrane (GBM) at immunofluorescence. Type 2 is a heterogeneous group of primary or secondary glomerular diseases complicated by crescentic GN. In this category there are granular deposits of immunoglobulins and complement fractions on the glomerular tuft. Type 3 includes cases of ANCA-associated small-vessel vasculitis. Immunofluorescence is negative or may show only faint deposits of immunoglobulins. The etiology and the initial pathogenetic factors are different in the three types, but the final mechanisms leading to crescent formation and the renal symptoms and signs are similar. The prognosis depends on the timeline of diagnosis and treatment. Although some patients requiring dialysis may recover a good renal function, usually the higher the serum creatinine at presentation the worse the outcome. When treatment is initiated early, most patients obtain a complete or partial remission. High-dose corticosteroids and cyclophosphamide represent the standard therapy for crescentic GN. The addition of plasma exchange may also be helpful, particularly in patients with massive alveolar hemorrhage. Anti-B monoclonal antibodies have also been used in some patients with crescentic GN, but their role in this particular area is still poorly established.

KW - ANCA-associated vasculitis (AAV)

KW - End stage renal disease

KW - Goodpasture syndrome

KW - Rapidly progressive glomerulonephritis

UR - http://www.scopus.com/inward/record.url?scp=84898837689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898837689&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2014.02.007

DO - 10.1016/j.autrev.2014.02.007

M3 - Article

C2 - 24657897

AN - SCOPUS:84898837689

VL - 13

SP - 723

EP - 729

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 7

ER -